<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37026395</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5-6</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Correlation between oculometric measures and clinical assessment in ALS patients participating in a phase IIb clinical drug trial.</ArticleTitle><Pagination><StartPage>495</StartPage><EndPage>501</EndPage><MedlinePgn>495-501</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2023.2196315</ELocationID><Abstract><AbstractText><i>Objective:</i> Oculometric measures (OM) can be extracted from eye movements during presentation of visual stimuli. Studies have indicated the benefit of OM in assessment of neurological disorders, including Amyotrophic Lateral Sclerosis (ALS). We used a new software-based platform for the extraction of OM during patients' assessment. Our objective was to examine the correlation between OM and clinical assessment as a part of a clinical drug trial. <i>Methods:</i> 32 ALS patients (mean age 60.75&#x2009;&#xb1;&#x2009;10.36 years, 13 females), were assessed using a validated score (ALSFRS-R), and a novel software-based oculometric platform (NeuraLight, Israel) as a part of a clinical drug trial. Correlations of ALSFRS-R with OM were calculated and compared with matched healthy subjects' data (<i>N</i>&#x2009;=&#x2009;129). <i>Results:</i> A moderate correlation was found between ALSFRS-R and corrective saccadic latency (<i>R</i>&#x2009;=&#x2009;0.52, <i>p</i>&#x2009;=&#x2009;0.002). Fixation time during smooth pursuit and peak velocity during pro-saccades&#xa0;were both worse in ALS patients versus healthy subjects (mean (SD)=0.34(0.06) vs. 0.3(0.07), <i>p</i>&#x2009;=&#x2009;0.01, and 0.41(0.05) vs. 0.38(0.07), <i>p</i>&#x2009;=&#x2009;0.04, respectively). Patients with bulbar symptoms (<i>N</i>&#x2009;=&#x2009;14) had a decreased pro-saccade gain compared with patients without bulbar symptoms (mean (SD)=0.1 (0.04) vs. 0.93 (0.07), <i>p</i>&#x2009;=&#x2009;0.01), and a larger error rate of anti-saccade movement (mean (SD)=0.42 (0.21) vs. 0.28 (0.16), <i>p</i>&#x2009;=&#x2009;0.04). <i>Conclusions:</i> Oculometric measures correlated with the clinical assessment and were different from data of healthy subjects. Further studies are warranted to establish the role of oculometrics in the evaluation of patients with ALS and other neurodegenerative disorders, and its possible use in clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raveh</LastName><ForeName>Eitan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NeuraLight Ltd., Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben-Shimon</LastName><ForeName>Assaf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NeuraLight Ltd., Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anisimov</LastName><ForeName>Vova</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>NeuraLight Ltd., Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreitman</LastName><ForeName>Rivka</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>NeuraLight Ltd., Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben-Ami</LastName><ForeName>Edmund</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NeuraLight Ltd., Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nechushtan</LastName><ForeName>Elisheva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Unit, Sackler Faculty of Medicine, Tel Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birman</LastName><ForeName>Nurit</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Unit, Sackler Faculty of Medicine, Tel Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drory</LastName><ForeName>Vivian E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Unit, Sackler Faculty of Medicine, Tel Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005133" MajorTopicYN="N">Eye Movements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012438" MajorTopicYN="N">Saccades</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Saccades</Keyword><Keyword MajorTopicYN="N">computer vision</Keyword><Keyword MajorTopicYN="N">error rate</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">smooth pursuit</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37026395</ArticleId><ArticleId IdType="doi">10.1080/21678421.2023.2196315</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>